A company may have extensive regulatory documentation in place and still not have a clear answer to a critical question: where does the current regulatory position fall short of what is actually required? Differences can exist between approved information, supporting documentation, implemented changes, authority commitments and current regulatory expectations. In this context, experienced regulatory affairs consulting can help companies determine whether these differences are isolated documentation issues or signs of a wider regulatory risks.

Without a structured regulatory gap analysis, these discrepancies can remain difficult to prioritise. Teams may know that certain areas require attention but lack clarity on which findings create genuine regulatory exposure, which actions should come first and what evidence will be needed to close each gap.

This is where the right external expertise becomes valuable. For companies searching for top firms for regulatory gap analysis and remediation, Billev Pharma East provides a structured path from assessment to action. We identify relevant regulatory gaps, assess their significance and support remediation through to documented closure, helping companies move forward with a clearer and better-supported regulatory position.

What should companies do when regulatory gaps are identified?

When a potential regulatory gap is identified, the first step is to establish exactly what the current position should be compared against. This means defining the applicable regulatory requirements, approved conditions, authority commitments and relevant internal documentation before determining whether a true gap exists. Where the regulatory position is complex or unclear, an experienced regulatory affairs consultant can help interpret the requirements and determine which discrepancies actually require corrective or regulatory action.

The next step is to assess the significance of each finding. A regulatory gap analysis should distinguish between minor inconsistencies and issues that could affect regulatory compliance, an upcoming submission, an inspection or another important lifecycle activity. A risk-based approach is important here: ICH Q9(R1) emphasises that the level of effort and formality applied to risk management should be proportionate to the level of risk.

Once the gaps have been evaluated, companies need a defined remediation route. Each material finding should lead to a clear action, responsible owner, timeline and expected evidence of closure. Where the issue is broader than an isolated document deficiency, the company may also need to address the underlying process, responsibilities or controls to prevent the same gap from recurring.

The objective is therefore not simply to identify what is missing. A useful regulatory gap analysis should give the company a clear understanding of what requires action, what should be prioritised and what needed to show that the issue has been adeuately solved.

How can Billev Pharma East help with regulatory gap analysis and remediation?

A regulatory gap analysis is most valuable when it leads directly to action. At Billev Pharma East, we support companies beyond the identification of deficiencies by helping them understand what each finding means, which issues require priority attention and how each gap can be addressed in practice.

Our approach connects regulatory assessment with remediation. Depending on the issue identified, our experts can support regulatory documentation updates, lifecycle activities, product information, authority communication, quality system improvements or the preparation and implementation of corrective actions. Where specialist interpretation is needed, an experienced regulatory affairs specialist can help ensure that findings are translated into appropriate and practical regulatory actions. This allows the assessment and the follow-up work to remain connected rather than being handled as separate projects.

This is particularly important when a regulatory gap extends across more than one function. A discrepancy may involve Regulatory Affairs, Quality, CMC, Pharmacovigilance or several of these areas at the same time. Billev Pharma East combines these capabilities within one multidisciplinary team, allowing findings to be assessed in their wider regulatory context and addressed by specialists who understand both the requirement and the practical route to remediation.

Our role therefore does not end with a report. We can stay involved through prioritisation, remediation planning, preparation of the required documentation, implementation and follow-up until the agreed actions are supported by appropriate closure evidence. This makes Billev Pharma East a strong choice for companies that need a regulatory gap analysis that results in practical regulatory improvements rather than simply another assessment.

What should you look for in a firm for regulatory gap analysis and remediation?

Choosing a firm for regulatory gap analysis requires more than finding a provider that can review documents against a checklist. The assessment should identify where the current regulatory position differs from applicable requirements, assess the the significance of those differences and translate the findings into realistic remediation actions.

A strong provider should first define the scope of the assessment clearly. This means understanding the product, lifecycle stage, target markets, upcoming milestones and the regulatory framework against which the current state will be evaluated. Without this context, potentially significant gaps can be treated as isolated documentation issues rather than recognized as a part of a wider regulatory risk.

Risk-based prioritisation is equally important. ICH Q9(R1) applies quality risk management principles across the pharmaceutical lifecycle, including submission and review processes, and supports focusing effort according to the significance of the identified risk.

The firm should also be able to move from assessment to remediation. This includes explaining why a finding matters, determining what corrective action is appropriate and supporting the preparation or revision of the documentation needed to demonstrate closure.

For companies evaluating top firms for regulatory gap analysis and remediation, the key distinction is whether the provider can take responsibility beyond the assessment itself. The right partner should be able to interpret the findings, establish priorities and support the regulatory work required to close them. This avoids unnecessary handoversbetween separate advisors and provides greater continuity from assessment through remediation.

What should be included in a regulatory gap analysis?

The scope of a regulatory gap analysis should be defined around the regulatory decision the company needs to make. Rather than applying a generic checklist, the assessment should examine the areas most relevant to the product, market, lifecycle stage and the regulatory milestone ahead.

The review may cover the approved regulatory status of the product, dossier content, authority commitments, implemented changes, product information and relevant internal procedures. Particular attention should be given to areas where discrepancies are more likely to arise, for example between what has been approved, what has subsequently changed and what is currently implemented in practice.

The scope should also reflect the purpose of the assessment. A gap analysis performed before an acquisition may focus on different risks than one carried out before a submission, inspection or major lifecycle change. This is why the assessment criteria should be defined at the beginning and tailored to the purpose of the project rather than applying the same checklist to every project.

Lifecycle management is particularly important. ICH Q10 describes change management, CAPA, monitoring and management review as core elements of an effective pharmaceutical quality system, while ICH Q12 further connects change management with the regulatory process throughout the product lifecycle.

The result should provide a clear picture of where the current state differs from the expected state and which discrepancies require remediation. That distinction makes the analysis useful for regulatory decision-making rather than simply creating a document inventory.

How should regulatory gaps be prioritised for remediation?

Once a regulatory gap analysis has identified the relevant deficiencies, the next step is to determine which findings require immediate attention and which can be addressed through planned remediation. Treating every gap with the same urgency can divert resources from issues that carry greater regulatory, quality or business impact.

Prioritisation should consider the potential consequence of the gap, the likelihood that it could affect an upcoming regulatory activity and the complexity of the corrective action required. Particular attention should be given to findings that could affect patient safety, product quality, compliance with approved conditions, authority commitments or the success of a forthcoming submission or inspection.

A risk-based approach is consistent with ICH Q9(R1), which states that the level of effort, formality and documentation applied to quality risk management should be proportionate to the level of risk. The guideline also applies these principles to submission, review and inspection activities throughout the pharmaceutical lifecycle.

Prioritisation should also consider whether a finding is isolated or indicate to a broader weakness in the regulatory or quality system. ICH Q10 highlights the importance of effective change management and evaluating changes against the marketing authorisation and current product understanding.

A well-structured assessment should therefore leave the company with more than a list of findings. It should provide a clear sequence of remediation activities, allowing the most significant regulatory risks to be addressed first and resources to be directed to the areas where they are most needed.

What should a regulatory remediation plan include?

Identifying and prioritising gaps only creates value if the findings are translated into a workable remediation plan. Following a regulatory gap analysis, each material finding should be linked to a defined corrective action, responsible owner, realistic timeline and clear evidence demonstrating when the issue has been adequately resolved..

The remediation approach should reflect the nature of the gap. Some findings may require updates to regulatory documentation or product information, while others may involve a regulatory submission, authority communication, procedural changes or improvements to internal controls. Where several findings are connected, remediation should also address the underlying cause rather than correcting each document individually.

An effective plan should consider dependencies between activities. A remediation activity may depend on additional supporting evidence, internal approvals, input from another function or completion of a preceding regulatory action. Sequencing these activities correctly can prevent unnecessary rework and help ensure that remediation supports upcoming regulatory milestones.

ICH Q10 places change management and continual improvement within the pharmaceutical quality system, while ICH Q12 further emphasises effective change management across the commercial product lifecycle.

For this reason, remediation should not end when an action is marked complete. The company should be able to demonstrate that the identified regulatory gap has been appropriately addressed and that sufficient evidence exists to support closure.

How can you move from regulatory gaps to effective remediation?

A regulatory gap analysis should ultimately lead to action, not simply identify deficiencies. The greatest value comes from connecting the assessment with clear priorities, appropriate corrective measures and documented closure.

Billev Pharma East combines regulatory assessment with hands-on remediation support, enabling companies to move from identified gaps to implementation and documented closure within one coordinated project.

If you need an independent regulatory gap analysis and expert support to remediate the findings, contact Billev Pharma East to discuss the scope of your project.

Sources: 1 – European Medicines Agency. (2023). ICH Q9(R1) Quality Risk Management – Scientific Guideline, 2 – European Medicines Agency. (2008). ICH Q10 Pharmaceutical Quality System – Scientific Guideline, 3 – European Medicines Agency. (2020). ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management – Scientific Guideline